| Bioactivity | YXG-158 (Compound 23-h) is an orally active AR degrader and CYP17A1 inhibitor. YXG-158 has AR degradation activity with DC50 value of 1.28 μM. YXG-158 can inhibit CYP17A1 with IC50 value of 100 nM. XG-158 can be used for the research of enzalutamide-resistant prostate cancer[1]. |
| Target | DC50: 1.28 μM (androgen receptor).IC50: 100 nM (CYP17A1). |
| Name | YXG-158 |
| CAS | 2952994-34-0 |
| Formula | C30H36FN3O |
| Molar Mass | 473.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang A, et al. Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. J Med Chem. 2023 Jul 27;66(14):9972-9991. |